

Jaime Bosch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8815222/publications.pdf>

Version: 2024-02-01

286
papers

37,523
citations

2203

99
h-index

3173

186
g-index

459
all docs

459
docs citations

459
times ranked

15737
citing authors

#	ARTICLE	IF	CITATIONS
1	Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. <i>Hepatology</i> , 2017, 65, 310-335.	3.6	1,520
2	Liver cirrhosis. <i>Lancet, The</i> , 2014, 383, 1749-1761.	6.3	1,425
3	Early Use of TIPS in Patients with Cirrhosis and Variceal Bleeding. <i>New England Journal of Medicine</i> , 2010, 362, 2370-2379.	13.9	1,075
4	The treatment of portal hypertension: A meta-analytic review. <i>Hepatology</i> , 1995, 22, 332-354.	3.6	1,015
5	Beta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis. <i>New England Journal of Medicine</i> , 2005, 353, 2254-2261.	13.9	952
6	Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated Cirrhosis. <i>Gastroenterology</i> , 2007, 133, 481-488.	0.6	926
7	Management of Varices and Variceal Hemorrhage in Cirrhosis. <i>New England Journal of Medicine</i> , 2010, 362, 823-832.	13.9	890
8	Baveno VII "Renewing consensus in portal hypertension. <i>Journal of Hepatology</i> , 2022, 76, 959-974.	1.8	890
9	Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure. <i>Gastroenterology</i> , 1996, 111, 1018-1022.	0.6	838
10	Pharmacological Treatment of Portal Hypertension: An Evidence-Based Approach. <i>Seminars in Liver Disease</i> , 1999, 19, 475-505.	1.8	730
11	Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. <i>Gastroenterology</i> , 1990, 99, 1401-1407.	0.6	679
12	The clinical use of HVPG measurements in chronic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 573-582.	8.2	576
13	Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. <i>Lancet, The</i> , 1995, 346, 1056-1059.	6.3	569
14	Improved clinical outcome using polytetrafluoroethylene-coated stents for tips: Results of a randomized study. <i>Gastroenterology</i> , 2004, 126, 469-475.	0.6	468
15	Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. <i>Hepatology</i> , 2003, 37, 902-908.	3.6	456
16	Elastography, Spleen Size, and Platelet Count Identify Portal Hypertension in Patients With Compensated Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 102-111.e1.	0.6	437
17	Prognostic value of early measurements of portal pressure in acute variceal bleeding. <i>Gastroenterology</i> , 1999, 117, 626-631.	0.6	435
18	Hepatic Vein Pressure Gradient Reduction and Prevention of Variceal Bleeding in Cirrhosis: A Systematic Review. <i>Gastroenterology</i> , 2006, 131, 1611-1624.	0.6	435

#	ARTICLE	IF	CITATIONS
19	Clinical events after transjugular intrahepatic portosystemic shunt: Correlation with hemodynamic findings. <i>Gastroenterology</i> , 1998, 114, 1296-1303.	0.6	431
20	Prevention of variceal rebleeding. <i>Lancet, The</i> , 2003, 361, 952-954.	6.3	398
21	Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: A randomized, double-blind trial. <i>Gastroenterology</i> , 2004, 127, 1123-1130.	0.6	386
22	Multiple emergences of genetically diverse amphibian-infecting chytrids include a globalized hypervirulent recombinant lineage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18732-18736.	3.3	375
23	β_2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2019, 393, 1597-1608.	6.3	375
24	Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial. <i>Gastroenterology</i> , 2009, 136, 1651-1658.	0.6	372
25	Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: Comparison with vasopressin. <i>Gastroenterology</i> , 1981, 80, 518-525.	0.6	342
26	Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. <i>Journal of Hepatology</i> , 2009, 50, 923-928.	1.8	340
27	Portal Hypertension and Its Complications. <i>Gastroenterology</i> , 2008, 134, 1715-1728.	0.6	303
28	A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding. <i>Gastroenterology</i> , 2014, 146, 412-419.e3.	0.6	285
29	Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. <i>Hepatology</i> , 2006, 43, 492-499.	3.6	282
30	Definitions, methodology and therapeutic strategies in portal hypertension. <i>Journal of Hepatology</i> , 1992, 15, 256-261.	1.8	273
31	Renal failure after upper gastrointestinal bleeding in cirrhosis: Incidence, clinical course, predictive factors, and short-term prognosis. <i>Hepatology</i> , 2001, 34, 671-676.	3.6	273
32	Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. <i>Hepatology</i> , 2009, 49, 1245-1256.	3.6	272
33	Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. <i>Hepatology</i> , 2008, 47, 1604-1614.	3.6	266
34	Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. <i>Lancet, The</i> , 1991, 337, 1431-1434.	6.3	264
35	Use of early-TIPS for high-risk variceal bleeding: Results of a post-RCT surveillance study. <i>Journal of Hepatology</i> , 2013, 58, 45-50.	1.8	259
36	Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. <i>Gastroenterology</i> , 2004, 126, 749-755.	0.6	258

#	ARTICLE	IF	CITATIONS
37	Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018, 155, 1140-1153.	0.6	253
38	Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. <i>Gastroenterology</i> , 1992, 103, 1909-1915.	0.6	252
39	Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study. <i>Hepatology</i> , 2016, 64, 2173-2184.	3.6	251
40	The management of portal hypertension: Rational basis, available treatments and future options. <i>Journal of Hepatology</i> , 2008, 48, S68-S92.	1.8	248
41	Current management of portal hypertension. <i>Journal of Hepatology</i> , 2003, 38, 54-68.	1.8	245
42	Comparison of Intravenous Somatostatin and Vasopressin Infusions in Treatment of Acute Variceal Hemorrhage. <i>Hepatology</i> , 1984, 4, 442-446.	3.6	243
43	Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. <i>Hepatology</i> , 2011, 54, 555-561.	3.6	240
44	Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. <i>Gastroenterology</i> , 2004, 126, 886-894.	0.6	236
45	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. <i>Gastroenterology</i> , 2016, 150, 1160-1170.e3.	0.6	232
46	Pharmacological Reduction of Portal Pressure and Long-Term Risk of First Variceal Bleeding in Patients with Cirrhosis. <i>American Journal of Gastroenterology</i> , 2006, 101, 506-512.	0.2	228
47	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. <i>Hepatology</i> , 2019, 70, 1913-1927.	3.6	226
48	<i>Escherichia coli</i> : an old friend with new tidings. <i>FEMS Microbiology Reviews</i> , 2016, 40, 437-463.	3.9	225
49	Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. <i>Hepatology</i> , 2017, 65, 1293-1305.	3.6	225
50	Functional aspects on the pathophysiology of portal hypertension in cirrhosis. <i>Journal of Hepatology</i> , 2012, 57, 458-461.	1.8	219
51	Measurement of Azygos Venous Blood Flow by a Continuous Thermal Dilution Technique: An Index of Blood Flow Through Gastroesophageal Collaterals in Cirrhosis. <i>Hepatology</i> , 1984, 4, 424-429.	3.6	211
52	Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. <i>Gastroenterology</i> , 2017, 153, 1273-1283.e1.	0.6	210
53	Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. <i>Journal of Hepatology</i> , 2007, 46, 1040-1046.	1.8	203
54	Multicenter Randomized Controlled Trial of Terlipressin Versus Sclerotherapy in the Treatment of Acute Variceal Bleeding: The TEST Study. <i>Hepatology</i> , 2000, 32, 471-476.	3.6	196

#	ARTICLE	IF	CITATIONS
55	Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. <i>Journal of Hepatology</i> , 2005, 43, 98-103.	1.8	196
56	Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. <i>Journal of Hepatology</i> , 2015, 62, S121-S130.	1.8	189
57	Real-time shear-wave elastography: Applicability, reliability and accuracy for clinically significant portal hypertension. <i>Journal of Hepatology</i> , 2015, 62, 1068-1075.	1.8	183
58	Measurement of Portal Pressure and Its Role in the Management of Chronic Liver Disease. <i>Seminars in Liver Disease</i> , 2006, 26, 348-362.	1.8	182
59	Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. <i>Hepatology</i> , 2010, 52, 2044-2052.	3.6	180
60	The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial stellate cell deactivation induced by statins. <i>Journal of Hepatology</i> , 2013, 58, 98-103.	1.8	180
61	Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. <i>Hepatology</i> , 2016, 63, 1957-1967.	3.6	174
62	Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury. <i>Journal of Hepatology</i> , 2019, 70, 458-469.	1.8	173
63	Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. <i>Hepatology</i> , 1990, 11, 230-238.	3.6	172
64	Atrial natriuretic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction. <i>Hepatology</i> , 1988, 8, 636-642.	3.6	170
65	Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. <i>Hepatology</i> , 2007, 46, 1208-1217.	3.6	166
66	KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. <i>Gut</i> , 2015, 64, 1434-1443.	6.1	159
67	Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. <i>Hepatology</i> , 1999, 30, 79-83.	3.6	158
68	Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. <i>Gastroenterology</i> , 1989, 96, 1110-1118.	0.6	153
69	Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. <i>Journal of Hepatology</i> , 2021, 75, S49-S66.	1.8	146
70	Preemptive TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. <i>Hepatology</i> , 2019, 69, 282-293.	3.6	144
71	Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension. <i>Hepatology</i> , 2016, 63, 197-206.	3.6	143
72	PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. <i>Hepatology</i> , 2004, 40, 1197-1202.	3.6	142

#	ARTICLE	IF	CITATIONS
73	Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. <i>Journal of Hepatology</i> , 2004, 41, 384-390.	1.8	141
74	Proteomic and phenotypic profiling of the amphibian pathogen <i>Batrachochytrium dendrobatidis</i> shows that genotype is linked to virulence. <i>Molecular Ecology</i> , 2009, 18, 415-429.	2.0	138
75	Continuous prazosin administration in cirrhotic patients: Effects on portal hemodynamics and on liver and renal function. <i>Gastroenterology</i> , 1995, 109, 1257-1265.	0.6	130
76	Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal-hypertensive rats. <i>Gastroenterology</i> , 1995, 108, 1487-1495.	0.6	127
77	Vascular Deterioration in Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, S247-S253.	1.1	126
78	Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats. <i>Hepatology</i> , 2001, 33, 821-825.	3.6	125
79	Mitigating amphibian chytridiomycoses in nature. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2016, 371, 20160207.	1.8	125
80	Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo-controlled clinical trial. <i>Hepatology</i> , 1989, 10, 962-968.	3.6	121
81	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. <i>Hepatology</i> , 2002, 36, 1367-1373.	3.6	121
82	Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 594-604.	5.2	119
83	Increased oxidative stress in cirrhotic rat livers: A potential mechanism contributing to reduced nitric oxide bioavailability. <i>Hepatology</i> , 2008, 47, 1248-1256.	3.6	118
84	Primary prophylaxis of variceal bleeding in children and the role of MesoRex Bypass: Summary of the Baveno VI Pediatric Satellite Symposium. <i>Hepatology</i> , 2016, 63, 1368-1380.	3.6	118
85	Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. <i>Journal of Hepatology</i> , 2013, 58, 904-910.	1.8	117
86	Gastric endoscopic features in portal hypertension: final report of a consensus conference, Milan, Italy, september 19, 1992. <i>Journal of Hepatology</i> , 1994, 21, 461-467.	1.8	116
87	Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. <i>Journal of Hepatology</i> , 2009, 51, 279-287.	1.8	116
88	Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. <i>Journal of Hepatology</i> , 2010, 52, 846-853.	1.8	114
89	Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: A double-blind hemodynamic investigation. <i>Hepatology</i> , 1995, 22, 106-111.	3.6	113
90	Invasive pathogens threaten species recovery programs. <i>Current Biology</i> , 2008, 18, R853-R854.	1.8	113

#	ARTICLE	IF	CITATIONS
91	Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. <i>Gut</i> , 2011, 60, 517-524.	6.1	113
92	Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. <i>Digestive and Liver Disease</i> , 2012, 44, 855-860.	0.4	113
93	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020, 73, 1082-1091.	1.8	112
94	Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. <i>Hepatology</i> , 1994, 19, 1095-1099.	3.6	111
95	Noninvasive measurement of the pressure of esophageal varices using an endoscopic gauge: Comparison with measurements by variceal puncture in patients undergoing endoscopic sclerotherapy. <i>Hepatology</i> , 1986, 6, 667-672.	3.6	110
96	Renin, aldosterone and renal haemodynamics in cirrhosis with ascites. <i>European Journal of Clinical Investigation</i> , 1979, 9, 69-73.	1.7	107
97	Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. <i>Journal of Viral Hepatitis</i> , 2017, 24, 823-831.	1.0	107
98	Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. <i>Journal of Hepatology</i> , 2020, 72, 885-895.	1.8	107
99	Impact of anticoagulation on upper gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. <i>Hepatology</i> , 2015, 62, 575-583.	3.6	105
100	Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. <i>Journal of Hepatology</i> , 2020, 73, 1415-1424.	1.8	104
101	Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. <i>Journal of Hepatology</i> , 2007, 47, 220-227.	1.8	100
102	Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: Influence of the extent of portal-systemic shunting. <i>Hepatology</i> , 1989, 9, 808-814.	3.6	99
103	Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. <i>Gut</i> , 2009, 58, 1144-1150.	6.1	98
104	Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. <i>Journal of Hepatology</i> , 2016, 64, 834-842.	1.8	97
105	Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension. <i>Gastroenterology</i> , 2018, 155, 1564-1577.	0.6	97
106	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. <i>Gastroenterology</i> , 2021, 160, 193-205.e10.	0.6	97
107	Addition of simvastatin to cold storage solution prevents endothelial dysfunction in explanted rat livers. <i>Hepatology</i> , 2012, 55, 921-930.	3.6	94
108	Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. <i>Hepatology</i> , 1995, 22, 753-758.	3.6	90

#	ARTICLE	IF	CITATIONS
109	Autoimmune hepatitis triggered by SARS-CoV-2 vaccination. <i>Journal of Autoimmunity</i> , 2021, 123, 102710.	3.0	89
110	Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension. <i>Hepatology</i> , 1988, 8, 850-854.	3.6	86
111	Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. <i>Hepatology</i> , 2013, 57, 1172-1181.	3.6	84
112	Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury. <i>Journal of Hepatology</i> , 2017, 66, 86-94.	1.8	84
113	The portal hypertension syndrome: etiology, classification, relevance, and animal models. <i>Hepatology International</i> , 2018, 12, 1-10.	1.9	81
114	Beta-blockers in cirrhosis: Evidence-based indications and limitations. <i>JHEP Reports</i> , 2020, 2, 100063.	2.6	81
115	Cirrhosis as new indication for statins. <i>Gut</i> , 2020, 69, 953-962.	6.1	81
116	Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis. <i>Hepatology</i> , 2017, 66, 1219-1231.	3.6	80
117	Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: Comparison with the effects on portal pressure. <i>Hepatology</i> , 1988, 8, 861-865.	3.6	78
118	Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. <i>Hepatology</i> , 2003, 37, 378-384.	3.6	78
119	How to Prevent Varices From Bleeding: Shades of Grey—The Case for Nonselective β^2 Blockers. <i>Gastroenterology</i> , 2007, 133, 2029-2036.	0.6	78
120	The role of portal pressure in the severity of bleeding in portal hypertensive rats. <i>Hepatology</i> , 2000, 31, 581-586.	3.6	77
121	CD84 Leukocyte Antigen Is a New Member of the Ig Superfamily. <i>Blood</i> , 1997, 90, 2398-2405.	0.6	76
122	Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: A clinical-hemodynamic correlation study. <i>Hepatology</i> , 2010, 51, 2108-2116.	3.6	74
123	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 313-327.e6.	2.4	74
124	Carvedilol for portal hypertension in patients with cirrhosis. <i>Hepatology</i> , 2010, 51, 2214-2218.	3.6	73
125	PPAR α activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. <i>Journal of Hepatology</i> , 2012, 56, 1033-1039.	1.8	73
126	Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. <i>Hepatology</i> , 2016, 63, 1640-1650.	3.6	73

#	ARTICLE	IF	CITATIONS
127	Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. <i>Journal of Hepatology</i> , 2021, 75, 1367-1376.	1.8	73
128	Reduction of variceal pressure by propranolol: Comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. <i>Hepatology</i> , 1993, 18, 1082-1089.	3.6	71
129	The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells. <i>Hepatology</i> , 2017, 65, 2031-2044.	3.6	71
130	Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. <i>Journal of Hepatology</i> , 2021, 74, 1188-1199.	1.8	70
131	Effects of propranolol on the hepatic hemodynamic response to physical exercise in patients with cirrhosis. <i>Hepatology</i> , 1998, 28, 677-682.	3.6	69
132	Emricasan (IDN6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension. <i>Hepatology</i> , 2019, 69, 717-728.	3.6	68
133	Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 20-30.	1.9	68
134	Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: Long-term hemodynamic and renal effects. <i>Hepatology</i> , 1994, 20, 1502-1508.	3.6	67
135	Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension. <i>Hepatology</i> , 1998, 27, 351-356.	3.6	64
136	Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. <i>Liver International</i> , 2014, 34, 16-25.	1.9	64
137	Varices and Variceal Hemorrhage in Cirrhosis: A New View of an Old Problem. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2109-2117.	2.4	64
138	Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. <i>Journal of Hepatology</i> , 2022, 77, 1014-1025.	1.8	64
139	Double-blind investigation of the effects of propranolol and placebo on the pressure of esophageal varices in patients with portal hypertension. <i>Hepatology</i> , 1991, 13, 917-922.	3.6	63
140	Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. <i>Hepatology</i> , 1993, 17, 800-806.	3.6	63
141	Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. <i>Journal of Hepatology</i> , 2008, 48, 61-67.	1.8	61
142	The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery. <i>Journal of Hepatology</i> , 2019, 71, 942-950.	1.8	61
143	Simvastatin maintains function and viability of steatotic rat livers procured for transplantation. <i>Journal of Hepatology</i> , 2013, 58, 1140-1146.	1.8	60
144	KLIC-score for predicting early failure in prosthetic joint infections treated with debridement, implant retention and antibiotics. <i>Clinical Microbiology and Infection</i> , 2015, 21, 786.e9-786.e17.	2.8	60

#	ARTICLE	IF	CITATIONS
145	Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1846-1853.e1.	2.4	60
146	Liver sinusoidal endothelial dysfunction after LPS administration: A role for inducible-nitric oxide synthase. <i>Journal of Hepatology</i> , 2014, 61, 1321-1327.	1.8	58
147	The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique. <i>Hepatology</i> , 2015, 62, 1584-1592.	3.6	57
148	Prevention and treatment of variceal haemorrhage in 2017. <i>Liver International</i> , 2017, 37, 104-115.	1.9	57
149	Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH. <i>Hepatology Communications</i> , 2020, 4, 1263-1278.	2.0	57
150	Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. <i>Hepatology</i> , 1994, 20, 30-33.	3.6	55
151	Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies. <i>Scientific Reports</i> , 2017, 7, 3255.	1.6	53
152	Effect of bolus injection and continuous infusion of somatostatin on gastric perfusion in cirrhotic patients with portal-hypertensive gastropathy. <i>Hepatology</i> , 1994, 20, 336-341.	3.6	52
153	Timing Affects Measurement of Portal Pressure Gradient After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension. <i>Gastroenterology</i> , 2017, 152, 1358-1365.	0.6	51
154	Development of a new protocol for rapid bacterial identification and susceptibility testing directly from urine samples. <i>Clinical Microbiology and Infection</i> , 2016, 22, 561.e1-561.e6.	2.8	49
155	Pathophysiology of portal hypertension. <i>Gastroenterology Clinics of North America</i> , 1992, 21, 1-14.	1.0	49
156	Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. <i>Hepatology</i> , 2013, 58, 2079-2088.	3.6	48
157	Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats. <i>Gut</i> , 2015, 64, 657-666.	6.1	48
158	New cellular and molecular targets for the treatment of portal hypertension. <i>Hepatology International</i> , 2015, 9, 183-191.	1.9	48
159	Transjugular local thrombolysis with/without TIPS in patients with acute non-cirrhotic, non-malignant portal vein thrombosis. <i>Digestive and Liver Disease</i> , 2017, 49, 1345-1352.	0.4	48
160	Reduction of gastric hyperemia by glypressin and vasopressin administration in cirrhotic patients with portal hypertensive gastropathy. <i>Hepatology</i> , 1994, 19, 55-60.	3.6	45
161	Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. <i>Hepatology</i> , 2019, 69, 1287-1299.	3.6	45
162	Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2022, 75, 1235-1246.	3.6	45

#	ARTICLE	IF	CITATIONS
163	Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. <i>Gastroenterology</i> , 1981, 80, 518-25.	0.6	45
164	Involvement of nitric oxide and prostaglandins in gastric mucosal hyperemia of portal-hypertensive anesthetized rats. <i>Hepatology</i> , 1993, 18, 628-634.	3.6	44
165	Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats. <i>Hepatology</i> , 2014, 60, 633-647.	3.6	44
166	Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum 1H-NMR Spectroscopy. <i>PLoS ONE</i> , 2016, 11, e0155094.	1.1	44
167	Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: An individual patient based meta-analysis of two controlled trials. <i>Journal of Hepatology</i> , 2014, 61, 252-259.	1.8	43
168	Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats. <i>Liver International</i> , 2017, 37, 1002-1012.	1.9	42
169	Effects of propranolol on gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. <i>Hepatology</i> , 1993, 17, 213-218.	3.6	41
170	Metformin reduces hepatic resistance and portal pressure in cirrhotic rats. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G301-G309.	1.6	40
171	Effects of metoclopramide and domperidone on azygos venous blood flow in patients with cirrhosis and portal hypertension. <i>Hepatology</i> , 1986, 6, 1244-1247.	3.6	38
172	Resemblance of the human liver sinusoid in a fluidic device with biomedical and pharmaceutical applications. <i>Biotechnology and Bioengineering</i> , 2018, 115, 2585-2594.	1.7	38
173	Gastric microcirculatory changes of Portal-hypertensive rats can be attenuated by long-term Estrogen-progestagen treatment. <i>Hepatology</i> , 1994, 20, 1261-1270.	3.6	37
174	Evidence Against a Role for NADPH Oxidase Modulating Hepatic Vascular Tone in Cirrhosis. <i>Gastroenterology</i> , 2007, 133, 959-966.	0.6	37
175	Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats. <i>Hepatology</i> , 2013, 58, 1424-1435.	3.6	37
176	Pharmacologic Management of Portal Hypertension. <i>Clinics in Liver Disease</i> , 2014, 18, 303-317.	1.0	37
177	Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism. <i>Hepatology Communications</i> , 2019, 3, 987-1000.	2.0	37
178	Pharmacologic prevention of variceal bleeding and rebleeding. <i>Hepatology International</i> , 2018, 12, 68-80.	1.9	36
179	Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 589-599.	1.8	36
180	Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis. <i>Hepatology</i> , 1995, 21, 83-88.	3.6	35

#	ARTICLE	IF	CITATIONS
181	Effects of warm ischemia and reperfusion on the liver microcirculatory phenotype of rats: underlying mechanisms and pharmacological therapy. <i>Scientific Reports</i> , 2016, 6, 22107.	1.6	35
182	Nuclear deformation mediates liver cell mechanosensing in cirrhosis. <i>JHEP Reports</i> , 2020, 2, 100145.	2.6	35
183	Small diameter shunts should lead to safe expansion of the use of TIPS. <i>Journal of Hepatology</i> , 2021, 74, 230-234.	1.8	34
184	Effects of propranolol on gastric microcirculation and acid secretion in portal hypertensive rats. <i>Hepatology</i> , 1990, 12, 476-480.	3.6	33
185	A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. <i>Hepatology</i> , 2020, 72, 1353-1365.	3.6	32
186	Simvastatin Attenuates Liver Injury in Rodents with Biliary Cirrhosis Submitted to Hemorrhage/Resuscitation. <i>Shock</i> , 2017, 47, 370-377.	1.0	30
187	Aging Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease. , 2019, 10, 684.		30
188	Impaired function of pancreatic islets from rats with portal hypertension resulting from cirrhosis and partial portal vein ligation. <i>Hepatology</i> , 1994, 19, 1257-1261.	3.6	29
189	Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?. <i>Journal of Hepatology</i> , 2022, 76, 458-463.	1.8	29
190	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , 2021, 75, 342-350.	1.8	28
191	Cardiovascular Risk Factors and Systemic Endothelial Function in Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2013, 108, 75-82.	0.2	27
192	Development of Analogues: Successes and Failures. <i>Scandinavian Journal of Gastroenterology</i> , 1998, 33, 3-13.	0.6	27
193	Patients Whose First Episode of Bleeding Occurs While Taking a β -Blocker Have High Long-term Risks of Rebleeding and Death. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 670-676.	2.4	26
194	Assessment of Hepatic Vascular Network Connectivity with Automated Graph Analysis of Dynamic Contrast-enhanced US to Evaluate Portal Hypertension in Patients with Cirrhosis: A Pilot Study. <i>Radiology</i> , 2015, 277, 268-276.	3.6	26
195	Anatomical differences in responsiveness to vasoconstrictors in the mesenteric veins from normal and portal hypertensive rats. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1996, 354, 474-480.	1.4	25
196	Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study. <i>American Journal of Gastroenterology</i> , 2015, 110, 985-992.	0.2	25
197	A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. <i>Hepatology</i> , 2021, 74, 3146-3160.	3.6	25
198	Long-term effects of distal splenorenal shunt on hepatic hemodynamics and liver function in patients with cirrhosis: Importance of reversal of portal blood flow. <i>Hepatology</i> , 1992, 15, 616-622.	3.6	24

#	ARTICLE	IF	CITATIONS
199	Pharmacological versus endoscopic therapy in the prevention of variceal hemorrhage: And the winner isâ€¦. <i>Hepatology</i> , 2009, 50, 674-677.	3.6	24
200	Patients With Signs of Advanced Liver Disease and Clinically Significant Portal Hypertension Do Not Necessarily Have Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2101-2109.e1.	2.4	24
201	Esophageal varices: Stage-dependent treatment algorithm. <i>Journal of Hepatology</i> , 2016, 64, 746-748.	1.8	23
202	A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients. <i>Scientific Reports</i> , 2017, 7, 10497.	1.6	23
203	Î²-Blockade with propranolol and hepatic artery blood flow in patients with cirrhosis. <i>Hepatology</i> , 1989, 10, 269-272.	3.6	22
204	Acute propranolol administration effectively decreases portal pressure in patients with TIPS dysfunction. <i>Gut</i> , 2003, 52, 130-133.	6.1	22
205	Management of gastrointestinal bleeding in patients with cirrhosis of the liver. <i>Seminars in Hematology</i> , 2004, 41, 8-12.	1.8	22
206	Prolonging Survival in Patients With Cirrhosis: Old Drugs With New Indications. <i>Gastroenterology</i> , 2010, 139, 1813-1815.e1.	0.6	22
207	Circulatory response to volume expansion and transjugular intrahepatic portosystemic shunt in refractory ascites: Relationship with diastolic dysfunction. <i>Digestive and Liver Disease</i> , 2015, 47, 1052-1058.	0.4	22
208	Impaired mesenteric leukocyte recruitment in experimental portal hypertension in the rat. <i>Hepatology</i> , 1999, 30, 445-453.	3.6	21
209	Variceal Bleeding: Pharmacological Therapy. <i>Digestive Diseases</i> , 2005, 23, 18-29.	0.8	21
210	Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease. <i>Hepatology Communications</i> , 2018, 2, 933-944.	2.0	21
211	Balloon Tamponade and Esophageal Stenting for Esophageal Variceal Bleeding in Cirrhosis: A Systematic Review and Meta-analysis. <i>Seminars in Liver Disease</i> , 2019, 39, 178-194.	1.8	21
212	Molecular cloning, characterization, and chromosomal localization of the mouse homologue of CD84, a member of the CD2 family of cell surface molecules. <i>Immunogenetics</i> , 1999, 49, 249-255.	1.2	20
213	A novel form of the human manganese superoxide dismutase protects rat and human livers undergoing ischaemia and reperfusion injury. <i>Clinical Science</i> , 2014, 127, 527-537.	1.8	20
214	Emerging therapies for portal hypertension in cirrhosis. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 167-181.	1.0	20
215	Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic rats. <i>Liver International</i> , 2020, 40, 2500-2514.	1.9	20
216	Gene structure of the mouse leukocyte cell surface molecule Ly9. <i>Immunogenetics</i> , 2000, 51, 788-793.	1.2	19

#	ARTICLE	IF	CITATIONS
217	Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, G496-G502.	1.6	19
218	Transcriptomic Profiling of the Liver Sinusoidal Endothelium during Cirrhosis Reveals Stage-Specific Secretory Signature. <i>Cancers</i> , 2021, 13, 2688.	1.7	18
219	New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease. <i>Cells</i> , 2019, 8, 1062.	1.8	17
220	Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis. <i>Liver International</i> , 2019, 39, 705-713.	1.9	17
221	Efficacy of somatostatin and vasopressin in the control of acute variceal hemorrhage. <i>Hepatology</i> , 1985, 5, 344-345.	3.6	15
222	Statins and liver disease: from concern to 'wonder' drugs?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 320-321.	8.2	15
223	Metabolomics as a diagnostic tool for idiopathic non-cirrhotic portal hypertension. <i>Liver International</i> , 2016, 36, 1051-1058.	1.9	15
224	Statins in cirrhosis—Ready for prime time. <i>Hepatology</i> , 2017, 66, 697-699.	3.6	15
225	The treatment of major complications of cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 1994, 8, 639-657.	1.9	14
226	Role and therapeutic potential of vascular stem/progenitor cells in pathological neovascularisation during chronic portal hypertension. <i>Gut</i> , 2017, 66, 1306-1320.	6.1	14
227	Ischemia/Reperfusion Injury in the Aged Liver: The Importance of the Sinusoidal Endothelium in Developing Therapeutic Strategies for the Elderly. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 75, 268-277.	1.7	14
228	A Nutraceutical Rich in Docosahexaenoic Acid Improves Portal Hypertension in a Preclinical Model of Advanced Chronic Liver Disease. <i>Nutrients</i> , 2019, 11, 2358.	1.7	13
229	A la carte or menu fixe: Improving pharmacologic therapy of portal hypertension. <i>Hepatology</i> , 2002, 36, 1330-1332.	3.6	12
230	Protein and miRNA profile of circulating extracellular vesicles in patients with primary sclerosing cholangitis. <i>Scientific Reports</i> , 2022, 12, 3027.	1.6	12
231	Prevention of Variceal Rebleeding: Endoscopes, Drugs, and More. <i>Hepatology</i> , 2000, 32, 660-662.	3.6	11
232	Exudative Ascites in the Course of Acute Type B Hepatitis. <i>Hepatology</i> , 2007, 3, 1013-1015.	3.6	11
233	Early periportal sinusoidal fibrosis is an accurate marker of accelerated HCV recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2014, 61, 270-277.	1.8	11
234	Prognosis of acute variceal bleeding: Is being on beta-blockers an aggravating factor? A short-term survival analysis. <i>Hepatology</i> , 2015, 62, 1840-1846.	3.6	11

#	ARTICLE	IF	CITATIONS
235	Beta-blockers in 2016: Still the safest and most useful drugs for portal hypertension?. <i>Hepatology</i> , 2016, 63, 1771-1773.	3.6	11
236	Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2020, 52, 958-965.	0.4	11
237	Carvedilol for preventing recurrent variceal bleeding: Waiting for convincing evidence. <i>Hepatology</i> , 2013, 57, 1665-1667.	3.6	10
238	Calculating Hepatic Venous Pressure Gradient: Feel Free to Stay Free. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1138-1139.	0.2	10
239	Impact of hepatic encephalopathy on liver transplant waiting list mortality in regions with different transplantation rates. <i>Clinical Transplantation</i> , 2018, 32, e13412.	0.8	9
240	Portal Hypertension and Cirrhosis: From Evolving Concepts to Better Therapies. <i>Clinical Liver Disease</i> , 2020, 15, S8-S12.	1.0	7
241	Correspondence. Is the Concept of "Exudative" Ascites Useful?. <i>Hepatology</i> , 1984, 4, 982-982.	3.6	6
242	Is treatment with nadolol effective against the growth of small esophageal varices in patients with cirrhosis?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2005, 2, 18-19.	1.7	6
243	An apology for beta blockers. <i>Journal of Hepatology</i> , 2014, 61, 450-451.	1.8	6
244	Dermatitis by <i>Dermatophilus congolensis</i> . <i>Clinical Microbiology and Infection</i> , 2015, 21, e73-e74.	2.8	6
245	EUS-guided intrahepatic portosystemic shunt: A real alternative to transjugular intrahepatic portosystemic shunt?. <i>Gastrointestinal Endoscopy</i> , 2017, 85, 248-249.	0.5	6
246	Letter: improve survival! Place early pre-emptive TIPSS in high-risk variceal bleeders. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 927-928.	1.9	5
247	Neutrophil adhesion is impaired in the mesentery but not in the liver sinusoids of portal hypertensive rats. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 280, G1351-G1359.	1.6	4
248	HVPG Measurements as a Surrogate of Clinical Events in Cirrhosis: Experience from Clinical Trials. <i>Current Hepatology Reports</i> , 2019, 18, 164-173.	0.4	4
249	Letter: nonselective beta-blockers, endoscopic therapy and portal vein thrombosis in cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1370-1371.	1.9	4
250	Involvement of nitric oxide and prostaglandins in gastric mucosal hyperemia of portal-hypertensive anesthetized rats. <i>Hepatology</i> , 1993, 18, 628-634.	3.6	4
251	Effect of bolus injection and continuous infusion of somatostatin on gastric perfusion in cirrhotic patients with portal-hypertensive gastropathy. <i>Hepatology</i> , 1994, 20, 336-341.	3.6	4
252	Editorial: increased cardiac output in cirrhosis "non-invasive assessment of regional blood flow by magnetic resonance angiography. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1340-1342.	1.9	3

#	ARTICLE	IF	CITATIONS
253	FIB-4 Improves LSM-Based Prediction of Complications in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2396-2398.e3.	2.4	3
254	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis. <i>JHEP Reports</i> , 2021, 3, 100368.	2.6	3
255	Impaired function of pancreatic islets from rats with portal hypertension resulting from cirrhosis and partial portal vein ligation. <i>Hepatology</i> , 1994, 19, 1257-1261.	3.6	3
256	Editorial: improving in-hospital management of decompensated cirrhosis by a "care bundle" – hope, frustration, and lessons to learn. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 754-755.	1.9	2
257	Royal Free Hospital – estimated glomerular filtration rate for prognostic stratification of first acute kidney injury in cirrhosis. <i>Liver International</i> , 2021, 41, 819-827.	1.9	2
258	Reply to: "Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma". <i>Journal of Hepatology</i> , 2022, 77, 567-568.	1.8	2
259	Reply:. <i>Hepatology</i> , 2002, 36, 260-260.	3.6	1
260	Is it tea time for portal hypertension?. <i>Clinical Science</i> , 2014, 126, 631-632.	1.8	1
261	Editorial: use of beta-blockers and of band ligation in preventing first and recurrent variceal bleeding – a real life vs evidence-based decisions. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1222-1223.	1.9	1
262	Bacteremia and intramniotic infection due to <i>Burkholderia cenocepacia</i> . <i>Clinical Microbiology and Infection</i> , 2020, 26, 1564-1565.	2.8	1
263	Double-blind investigation of the effects of propranolol and placebo on the pressure of esophageal varices in patients with portal hypertension. <i>Hepatology</i> , 1991, 13, 917-922.	3.6	1
264	Treatment of variceal bleeding in patients with cirrhosis of the liver. <i>Clinical Intensive Care: International Journal of Critical & Coronary Care Medicine</i> , 2005, 16, 111-119.	0.1	0
265	OP25.08: Cervical length and gestational age at admission as predictors of intra-amniotic inflammation in preterm labor with intact membranes. <i>Ultrasound in Obstetrics and Gynecology</i> , 2009, 34, 145-145.	0.9	0
266	Reply:. <i>Hepatology</i> , 2011, 53, 2141-2142.	3.6	0
267	EASL Recognition Award Recipient 2015. <i>Journal of Hepatology</i> , 2015, 63, 787-788.	1.8	0
268	EASL International Recognition Award Recipient 2016: Prof. Roberto J. Groszmann. <i>Journal of Hepatology</i> , 2016, 64, 996-997.	1.8	0
269	Reply. <i>Hepatology</i> , 2016, 64, 2274-2274.	3.6	0
270	Reply. <i>Gastroenterology</i> , 2016, 151, 1037-1038.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Reply. Hepatology, 2017, 65, 2121-2122.	3.6	0
272	Reply. Hepatology, 2017, 65, 386-387.	3.6	0
273	Muscle abnormalities in cirrhosis: Calling for more strength in evaluation and prevention. Digestive and Liver Disease, 2019, 51, 1500-1501.	0.4	0
274	Skin infection by Corynebacterium diphtheriae and Streptococcus pyogenes: an unusual association. Enfermedades Infecciosas Y Microbiología Clínica, 2019, 37, 678-679.	0.3	0
275	Reply. Hepatology, 2019, 70, 1079-1080.	3.6	0
276	Reply to: "Achieving an effective pressure reduction after TIPS: The need for a new target". Journal of Hepatology, 2021, 75, 248-249.	1.8	0
277	Annals for Hospitalists Inpatient Notes - Clinical Pearls "Hepatorenal Syndrome. Annals of Internal Medicine, 2021, 174, HO2-HO3.	2.0	0
278	Reply to: "First things first! Can bacterial infections be considered as decompensating events per se?". Journal of Hepatology, 2021, 75, 1242-1243.	1.8	0
279	Treatment of variceal bleeding in patients with cirrhosis of the liver. Clinical Intensive Care: International Journal of Critical & Coronary Care Medicine, 2005, 16, 111-119.	0.1	0
280	Hepatopulmonary syndrome and portopulmonary hypertension. , 0, , 751-756.		0
281	Adenocarcinoma (Gastric Cancer and Miscellaneous Malignancy). , 0, , 248-253.		0
282	Functional Gastrointestinal Disease. , 0, , 54-60.		0
283	Reply. Hepatology, 2022, 76, E5-E6.	3.6	0
284	Evaluation of the portal hypertensive patient. Journal of Gastroenterology and Hepatology (Australia), 1989, 4 Suppl 1, 39-47.	1.4	0
285	Diagnosis and evaluation of portal hypertension. Zeitschrift Fur Gastroenterologie, 1988, 26 Suppl 2, 8-14.	0.2	0
286	Investigational drugs in early clinical development for portal hypertension. Expert Opinion on Investigational Drugs, 2022, 31, 825-842.	1.9	0